Key result
Finerenone significantly reduced the risk of cardiovascular events by 12% (RR 0.88) compared to placebo in patients with chronic kidney disease and type 2 diabetes.
Why the study?
Recent RCTs suggested that finerenone reduced cardiovascular events in patients with CKD and DM-2, prompting a meta-analysis to evaluate these cardiovascular benefits.
Does finerenone reduce cardiovascular events in patients with chronic kidney disease and type 2 diabetes?
Meta-Analysis (n=13,847)
Does finerenone reduce cardiovascular events in patients with chronic kidney disease and type 2 diabetes?
Relative Risk: 0.88 (95% CI 0.8–0.96)
p-value: p=< 0.01
In patients with chronic kidney disease and type 2 diabetes, finerenone significantly reduces cardiovascular events, a benefit primarily driven by a reduction in heart failure hospitalizations.
Supports finerenone for CV risk reduction in CKD with T2DM; confirms benefit across three RCTs.
Recently, a few randomized control trials (RCTs) suggested that finerenone has been shown to reduce cardiovascular events in patients with CKD and DM-2. We aimed to analyze the cardiovascular benefits of using finerenone in patients with CKD and DM-2. Electronic databases were systematically searched to identify only RCTs comparing finerenone versus placebo. Pooled risk ratios (RR) and their 95% confidence intervals (CI) were calculated using random-effects models. Three RCTs were included, with a total of 13,847 patients. Compared with the placebo group, the use of finerenone was associated with significantly lower rates of cardiovascular events (RR: 0.88; 95% CI: 0.80, 0.96; p < 0.01), which was mainly driven by lower hospitalizations for heart failure (RR: 0.79; 95% CI: 0.66, 0.94; p = 0.01). However, there were no significant differences between groups in terms of cardiovascular death (RR: 0.88; 95% CI: 0.76, 1.02; p = 0.09), non-fatal myocardial infarction (RR: 0.91; 95% CI: 0.74, 1.12;p = 0.38), non-fatal stroke (RR: 0.99; 95% CI: 0.80, 1.22; p = 0.90).
No takes yet. Share an insight, caveat, or question.
Abdelazeem et al. (2022) conducted a meta-analysis in Chronic kidney disease and type 2 diabetes (n=13,847). Finerenone vs. Placebo was evaluated on Cardiovascular events (composite of death from cardiovascular causes, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for heart failure) (RR 0.88, 95% CI 0.80, 0.96, p=< 0.01). Finerenone significantly reduced the risk of cardiovascular events by 12% (RR 0.88) compared to placebo in patients with chronic kidney disease and type 2 diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: